Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment-Reference-Cited by-同舟云学术

Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment

Published:2021-06-24 Issue:12 Volume:27 Page:1960-1964
ISSN:1352-4585
Container-title:Multiple Sclerosis Journal
language:en
Short-container-title:Mult Scler

Author:

Schönfelder Kristina¹,Schuh Helene²,Pfister Frederick³,Krämer Julia⁴,Eisenberger Ute¹,Skuljec Jelena²,Hackert Jana²,Ruck Tobias⁴,Pfeuffer Steffen⁴^ORCID,Fleischer Michael²,Gäckler Anja¹,Hagenacker Tim²,Kribben Andreas¹,Meuth Sven G⁴,Kleinschnitz Christoph²,Pul Refik²

Affiliation:

1. Department of Nephrology, University Medicine Essen, Essen, Germany Center for Translational Neuro- and Behavioral Sciences, University Hospital Essen, Essen, Germany

2. Department of Neurology, University Medicine Essen, Essen, Germany/Center for Translational Neuro- and Behavioral Sciences, University Hospital Essen, Essen, Germany

3. Department of Nephropathology, University Medicine Erlangen, Erlangen, Germany

4. Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany

Abstract

Background: Oral cladribine is an approved disease-modifying drug for the treatment of relapsing multiple sclerosis. In controlled clinical trials as well as in post marketing safety assessments, autoimmune conditions have not yet been reported as a specific side effect of cladribine. Objective and Results: Here, we report a case of anti-glomerular basement membrane antibody-mediated glomerulonephritis that occurred shortly after the fourth cladribine treatment cycle. Conclusion: Neurologists should be attentive to the development of secondary autoimmunity in cladribine-treated patients.

Publisher

SAGE Publications

Subject

Neurology (clinical),Neurology

Link

http://journals.sagepub.com/doi/pdf/10.1177/13524585211022719

Reference15 articles.

1. Cladribine (2-chlorodeoxyadenosine)

2. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis

3. Potential mechanisms of action related to the efficacy and safety of cladribine

4. A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The coincidence of multiple sclerosis and primary vasculitis; from the bench of pathology to the bedside of treatment: a systematic review of case reports;Neurological Sciences;2024-09-04

2. Hepatobiliary Adverse Reactions during Treatment with Cladribine: Analysis of Data from the European Spontaneous Reporting System;Pharmaceuticals;2023-07-27

3. Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety;Wiener Medizinische Wochenschrift;2022-04-22

4. Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review;Neurology and Therapy;2022-03-23

5. Cladribine;Reactions Weekly;2021-11